Provided herein are methods of treating and preventing hereditary angioedema attack in pediatric subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 150 mg every two weeks or at about 150 mg every four weeks.

The present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration of diabetic complications or angioedema containing a mixed extract of Hedera helix leaves and Coptis chinensis as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration of diabetic complications or angioedema further containing an extract of Rheum palmatum, Puerariae radix, Ginkgo leaves, Cassiae semen, blueberry, bilberry, raspberry, or grape seeds as an active ingredient, in addition to the mixed extract of Hedera helix leaves and Coptis chinensis.

An object of the present disclosure is at least to provide a technique for improving QOL of a 40-year-old or older postmenopausal woman without menopausal disorder, and the object is achieved by a composition for improving QOL of a 40-year-old or older postmenopausal woman without menopausal disorder, comprising equols.

Coagglomerates of mannitol, whose laser volume-average diameter D4,3 is between 1 and 200 μm, and of granular starch, are characterized in that they have a disintegration behavior determined according to a test A such that the relaxation time measured is between 30 and 100 seconds and the swelling force is between 0.8 and 3.0 N.

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included. ##STR00001##

The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: ##STR00001##
where R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.4′, X.sub.1, Y.sub.1, Y.sub.2, Y.sub.3, Y.sub.4, n, and m are described herein.

The present invention provides a composition for improving lymphatic circulation, which contains a component selected from at least one highly unsaturated fatty acid, salt thereof, and ester thereof as an active ingredient. The present invention also provides a composition for improving lymphatic circulation, which contains as active ingredients a triglyceride comprising the at least one highly unsaturated fatty acid as a constituent fatty acid and a triglyceride comprising the at least one middle chain fatty acid as a constituent fatty acid. The present invention also provides a composition for improving lymphatic circulation, which contains as an active ingredient a triglyceride comprising the at least one highly unsaturated fatty acid and the at least one middle chain fatty acid as constituent fatty acids.

The present invention provides a composition for improving lymphatic circulation, which contains a component selected from at least one highly unsaturated fatty acid, salt thereof, and ester thereof as an active ingredient. The present invention also provides a composition for improving lymphatic circulation, which contains as active ingredients a triglyceride comprising the at least one highly unsaturated fatty acid as a constituent fatty acid and a triglyceride comprising the at least one middle chain fatty acid as a constituent fatty acid. The present invention also provides a composition for improving lymphatic circulation, which contains as an active ingredient a triglyceride comprising the at least one highly unsaturated fatty acid and the at least one middle chain fatty acid as constituent fatty acids.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, the present invention relates generally to the treatment of eosinophilic bronchitis with an anti-IL-5 antibody or fragment thereof.